Review



pam2csk4 tlr2 tlr6 agonist  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    InvivoGen pam2csk4 tlr2 tlr6 agonist
    Pam2csk4 Tlr2 Tlr6 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 607 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/Pam2CSK4/pmc13127319-17-0-5
    Average 96 stars, based on 607 article reviews
    pam2csk4 tlr2 tlr6 agonist - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Copper-Induced Expression of a Transmissible Lipoprotein Intramolecular Transacylase Alters Lipoprotein Acylation and the Toll-Like Receptor 2 Response to Listeria monocytogenes
    Article Snippet: .. HEK293 NF-κB/SEAP-reporter cells (HEK-Blue) expressing human TLR2/TLR1/TLR6, TLR2/TLR1, and TLR2/TLR6 (InvivoGen, San Diego, CA) were cultivated in 75-cm 2 culture flasks in 15 ml Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM l -glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml Normocin (InvivoGen), and 4 μl/ml HEK-Blue selection antibiotics at 37°C in 5% CO 2 . .. The triacylated Pam 3 CSK 4 and diacylglycerol-modified Pam 2 CSK 4 and FSL-1 (Pam 2 CGDPKHPKSF) synthetic lipopeptides were purchased from InvivoGen and the lyso form PamC(Pam)SK 4 from EMC Microcollections (Tubingen, Germany).

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity.
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..

    Modification:

    Article Title: Copper-Induced Expression of a Transmissible Lipoprotein Intramolecular Transacylase Alters Lipoprotein Acylation and the Toll-Like Receptor 2 Response to Listeria monocytogenes
    Article Snippet: .. HEK293 NF-κB/SEAP-reporter cells (HEK-Blue) expressing human TLR2/TLR1/TLR6, TLR2/TLR1, and TLR2/TLR6 (InvivoGen, San Diego, CA) were cultivated in 75-cm 2 culture flasks in 15 ml Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM l -glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml Normocin (InvivoGen), and 4 μl/ml HEK-Blue selection antibiotics at 37°C in 5% CO 2 . .. The triacylated Pam 3 CSK 4 and diacylglycerol-modified Pam 2 CSK 4 and FSL-1 (Pam 2 CGDPKHPKSF) synthetic lipopeptides were purchased from InvivoGen and the lyso form PamC(Pam)SK 4 from EMC Microcollections (Tubingen, Germany).

    Article Title: Small molecule compound inhibiting signal transmission path of TLR7 and TLR9 and use thereof
    Article Snippet: The cells were cultured in RPMI 1640 (HyClone Laboratories, Inc.) and t differentiated into macrophages by applying 80 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Co., St. Louis, MO, USA) for 48 h. All cell lines were maintained in a humidified incubator (37° C., 5% CO2), and the medium was replaced after overnight incubation. .. Agonists specific to TLR1/TLR2 (Pam3CSK4), TLR2/TLR6 (FSL-1), TLR3 (Poly I:C), TLR7 (imiquimod), and TLR8 (TL8-506) were purchased from InvivoGen Ltd. (Hong-Kong, China), and a TLR4-specific agonist (LPS from E. coli O111:B4) was purchased from Sigma-Aldrich, Inc. For TLR9-specific stimulation, class C CpG-ODN (ODN2395, 5′-TCG TCG TTT TCG GCG CGC GCC G-3′) having full phosphorothioate backbone modification was synthesized (Bioneer, Inc., Daejeon, Korea). ..

    Selection:

    Article Title: Copper-Induced Expression of a Transmissible Lipoprotein Intramolecular Transacylase Alters Lipoprotein Acylation and the Toll-Like Receptor 2 Response to Listeria monocytogenes
    Article Snippet: .. HEK293 NF-κB/SEAP-reporter cells (HEK-Blue) expressing human TLR2/TLR1/TLR6, TLR2/TLR1, and TLR2/TLR6 (InvivoGen, San Diego, CA) were cultivated in 75-cm 2 culture flasks in 15 ml Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM l -glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 100 mg/ml Normocin (InvivoGen), and 4 μl/ml HEK-Blue selection antibiotics at 37°C in 5% CO 2 . .. The triacylated Pam 3 CSK 4 and diacylglycerol-modified Pam 2 CSK 4 and FSL-1 (Pam 2 CGDPKHPKSF) synthetic lipopeptides were purchased from InvivoGen and the lyso form PamC(Pam)SK 4 from EMC Microcollections (Tubingen, Germany).

    Synthesized:

    Article Title: Small molecule compound inhibiting signal transmission path of TLR7 and TLR9 and use thereof
    Article Snippet: The cells were cultured in RPMI 1640 (HyClone Laboratories, Inc.) and t differentiated into macrophages by applying 80 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Co., St. Louis, MO, USA) for 48 h. All cell lines were maintained in a humidified incubator (37° C., 5% CO2), and the medium was replaced after overnight incubation. .. Agonists specific to TLR1/TLR2 (Pam3CSK4), TLR2/TLR6 (FSL-1), TLR3 (Poly I:C), TLR7 (imiquimod), and TLR8 (TL8-506) were purchased from InvivoGen Ltd. (Hong-Kong, China), and a TLR4-specific agonist (LPS from E. coli O111:B4) was purchased from Sigma-Aldrich, Inc. For TLR9-specific stimulation, class C CpG-ODN (ODN2395, 5′-TCG TCG TTT TCG GCG CGC GCC G-3′) having full phosphorothioate backbone modification was synthesized (Bioneer, Inc., Daejeon, Korea). ..

    Stable Transfection:

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity.
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..

    Control:

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity.
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..

    Article Title: Human herpesviruses-encoded dUTPases: a family of proteins that modulate dendritic cell function and innate immunity
    Article Snippet: .. Human embryonic kidney 293 (HEK293) cell lines stably expressing either human TLR2 (TLR2-HEK293) or TLR2/TLR6 (TLR2/TLR6-HEK293) as well as control cells (HEK293 WT) were purchased from Invivogen (San Diego, CA). ..



    Similar Products

    pam2csk4 tlr2 tlr6 agonist  (InvivoGen)
    96
    InvivoGen pam2csk4 tlr2 tlr6 agonist
    Pam2csk4 Tlr2 Tlr6 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/Pam2CSK4/pmc13127319-17-0-5
    Average 96 stars, based on 1 article reviews
    pam2csk4 tlr2 tlr6 agonist - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    fsl1 tlr2 tlr6  (InvivoGen)
    96
    InvivoGen fsl1 tlr2 tlr6
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Fsl1 Tlr2 Tlr6, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/FSL-1/bio_rxiv__64898__2026__05__07__723498-68-16-34
    Average 96 stars, based on 1 article reviews
    fsl1 tlr2 tlr6 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    tlr2 tlr6 agonist pam2csk4  (InvivoGen)
    96
    InvivoGen tlr2 tlr6 agonist pam2csk4
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Tlr2 Tlr6 Agonist Pam2csk4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/Pam2CSK4/pm42105949-77-55-60
    Average 96 stars, based on 1 article reviews
    tlr2 tlr6 agonist pam2csk4 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    tlr2 tlr6 agonist tlrl fsl  (InvivoGen)
    96
    InvivoGen tlr2 tlr6 agonist tlrl fsl
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Tlr2 Tlr6 Agonist Tlrl Fsl, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/FSL-1/10__5152_slash_archrheumatol__2026__25179-41-16-40
    Average 96 stars, based on 1 article reviews
    tlr2 tlr6 agonist tlrl fsl - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    tlr2 tlr6  (InvivoGen)
    96
    InvivoGen tlr2 tlr6
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Tlr2 Tlr6, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/FSL-1/us12565475-179-5-18
    Average 96 stars, based on 1 article reviews
    tlr2 tlr6 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    fsl 1 tlr2 tlr6 ligand  (InvivoGen)
    96
    InvivoGen fsl 1 tlr2 tlr6 ligand
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Fsl 1 Tlr2 Tlr6 Ligand, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/FSL-1/bio_rxiv__64898__2025__12__29__696918-78-18-24
    Average 96 stars, based on 1 article reviews
    fsl 1 tlr2 tlr6 ligand - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    human tlr2 tlr6 nf κb seap  (InvivoGen)
    94
    InvivoGen human tlr2 tlr6 nf κb seap
    Analysis of the effect of LPS on BacSp222-dependent activation of the <t>TLR2/TLR6</t> heterodimer. HEK-Blue <t>hTLR2/TLR6</t> cells were incubated for 17 h in medium or stimulated with 0.05 μM BacSp222, 5 μg/mL LPS, or 0.05 μM BacSp222 + 5 μg/mL LPS in the presence or absence of FBS. Then, the SEAP activity was measured in postcultured media. The bars represent the mean ± SD ( n = 3), * p < 0.05, *** p < 0.001 vs LPS-treated cells.
    Human Tlr2 Tlr6 Nf κb Seap, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/HEK-Blue+hTLR2-TLR6+Cells/pmc12340957-184-5-17
    Average 94 stars, based on 1 article reviews
    human tlr2 tlr6 nf κb seap - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    lipopeptide 2 malp 2  (Novus Biologicals)
    93
    Novus Biologicals lipopeptide 2 malp 2
    Analysis of the effect of LPS on BacSp222-dependent activation of the <t>TLR2/TLR6</t> heterodimer. HEK-Blue <t>hTLR2/TLR6</t> cells were incubated for 17 h in medium or stimulated with 0.05 μM BacSp222, 5 μg/mL LPS, or 0.05 μM BacSp222 + 5 μg/mL LPS in the presence or absence of FBS. Then, the SEAP activity was measured in postcultured media. The bars represent the mean ± SD ( n = 3), * p < 0.05, *** p < 0.001 vs LPS-treated cells.
    Lipopeptide 2 Malp 2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr6/MALP-2%2C+TLR6+and+TLR2+ligand/pm39940697-303-19-22
    Average 93 stars, based on 1 article reviews
    lipopeptide 2 malp 2 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.

    Journal: bioRxiv

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction

    doi: 10.64898/2026.05.07.723498

    Figure Lengend Snippet: (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.

    Article Snippet: The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).

    Techniques: Expressing, Control, Activity Assay, RNA Sequencing, Cell Culture, Gene Expression, Quantitative RT-PCR

    Analysis of the effect of LPS on BacSp222-dependent activation of the TLR2/TLR6 heterodimer. HEK-Blue hTLR2/TLR6 cells were incubated for 17 h in medium or stimulated with 0.05 μM BacSp222, 5 μg/mL LPS, or 0.05 μM BacSp222 + 5 μg/mL LPS in the presence or absence of FBS. Then, the SEAP activity was measured in postcultured media. The bars represent the mean ± SD ( n = 3), * p < 0.05, *** p < 0.001 vs LPS-treated cells.

    Journal: ACS Infectious Diseases

    Article Title: Interactions between Lipopolysaccharide and Peptide Bacteriocin BacSp222 Influence Their Biological Activities

    doi: 10.1021/acsinfecdis.5c00066

    Figure Lengend Snippet: Analysis of the effect of LPS on BacSp222-dependent activation of the TLR2/TLR6 heterodimer. HEK-Blue hTLR2/TLR6 cells were incubated for 17 h in medium or stimulated with 0.05 μM BacSp222, 5 μg/mL LPS, or 0.05 μM BacSp222 + 5 μg/mL LPS in the presence or absence of FBS. Then, the SEAP activity was measured in postcultured media. The bars represent the mean ± SD ( n = 3), * p < 0.05, *** p < 0.001 vs LPS-treated cells.

    Article Snippet: Human TLR4/NF-κB/SEAP (HEK-Blue hTLR4) and human TLR2 + TLR6/NF-κB/SEAP (HEK-Blue hTLR2/TLR6) reporter HEK293 cells were obtained from InvivoGen (San Diego, CA, USA).

    Techniques: Activation Assay, Incubation, Activity Assay